Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes

Therapeutic Advances in Drug Safety

Volumn 2, Issue 5, 2011, Pages 213-225

  Shapiro, Amy D ^a   Hedner, Ulla ^b  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

hemophilia; inhibitors; outcomes; patient care; plasma derived activated prothrombin complex concentrate; recombinant activated factor VII

Indexed keywords

EID: 84993804280     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098611415566     Document Type: Review

References (80)

1. Abshire T. Kenet G. (2008) Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 14: 898–902.
2. Ahlberg A. Nilsson I.M. Bauer G.C. (1965) Use of antihemophilic factor (plasma fraction I-O) during correction of knee-joint deformities in hemophilia A. Report of three cases including one osteotomy. J Bone Joint Surg Am 47: 323–332.
3. Aledort L.M. (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2: 1700–1708.
4. Balkan C. Karapinar D. Aydogdu S. Ozcan C. Ay Y. Akin M. (2010) Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia 16: 902–909.
5. Baxter Healthcare (2010) FEIBA-NF [Anti-Inhibitor Coagulant Complex] Nanofiltered and Vapor Heated, Lypohilized powder for solution, Intravenous. Baxter Healthcare Corporation: Westlake Village, CA.
6. Brinkhous K.M. Hedner U. Garris J.B. Diness V. Read M.S. (1989) Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 86: 1382–1386.
7. Bysted B.V. Scharling B. Moller T. Hansen B.L. (2007) A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 13: 527–532.
8. Cooper H.A. Jones C.P. Campion E. Roberts H.R. Hedner U. (2001) Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 7: 517–522.
9. DiMichele D. (2007) Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 5(Suppl. 1): 143–150.
10. DiMichele D. (2008) Inhibitors in Hemophilia: A Primer 4th. World Federation of Hemophilia: Montreal, Quebec.
11. Ehrlich H.J. Henzl M.J. Gomperts E.D. (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8: 83–90.
12. Franchini M. Lippi G. (2010) Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 36: 485–492.
13. Fridberg M.J. Hedner U. Roberts H.R. Erhardtsen E. (2005) A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 16: 259–266.
14. Gomperts E.D. (2006) FEIBA safety and tolerability profile. Haemophilia 12: 14–19.
15. Green D. (1971) Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 37: 381–387.
16. Hedner U. Erhardtsen E. (2003) Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 1: 112–119.
17. Hedner U. Ezban M. (2008) Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 59: 29–41.
18. Hedner U. Ingerslev J. (1998) Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 19: 163–176.
19. Hedner U. Ljundberg J. Lund-Hansen T. (1990) Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coagul Fibrinolysis 1: 145–151.
20. Hedner U. Nilsson I.M. (1983) Induced tolerance in hemophilia patients with antibodies against IX:C. Acta Med Scand 214: 191–197.
21. Hedner U. Sundqvist S.B. Nilsson I.M. (1982) Immunosuppressive Treatment in Hemophiliacs with Inhibitors. Praeger Publishers: New York.
22. Hilgartner M.W. Makipernaa A. DiMichele D.M. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 9: 261–268.
23. Hoffman M. Monroe D.M. (2010) Platelet binding and activity of recombinant factor VIIa. Thromb Res 125(Suppl. 1): S16–S18.
24. Hoots W.K. Ebbesen L.S. Konkle B.A. Auerswald G.K. Roberts H.R. Weatherall J. (2008) Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 14: 466–475.
25. Ingerslev J. Freidman D. Gastineau D. Gilchrist G. Johnsson H. Lucas G. (1996) Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 26(Suppl. 1): 118–123.
26. Johansson P.I. Ostrowski S.R. (2010) Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Des Devel Ther 4: 107–116.
27. Kasper C.K. (1979) Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 54: 1358–1368.
28. Kavakli K. Makris M. Zulfikar B. Erhardtsen E. Abrams Z.S. Kenet G. (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 95: 600–605.
29. Kempton C.L. Soucie J.M. Abshire T.C. (2006) Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 4: 2576–2581.
30. Kenet G. Lubetsky A. Luboshitz J. Martinowitz U. (2003) A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1: 450–455.
31. Kenet G. Stenmo C.B. Blemings A. Wegert W. Goudemand J. Krause M. (2010) Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 103: 351–359.
32. Key N.S. Aledort L.M. Beardsley D. Cooper H.A. Davignon G. Ewenstein B.M. (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80: 912–918.
33. Key N.S. Nelsestuen G.L. (2004) Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 41(1 Suppl. 1): 51–54.
34. Klitgaard T. Nielsen T.G. (2008) Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 65: 3–11.
35. Klitgaard T. Tabanera y Palacios R. Boffard K.D. Iau P.T. Warren B. Rizoli S. (2006) Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care 10: R104–R104.
36. Konkle B.A. Ebbesen L.S. Erhardtsen E. Bianco R.P. Lissitchkov T. Rusen L. (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5: 1904–1913.
37. Kreuz W. Escuriola-Ettinghausen C. Martinez I. Mentzer D. Figura S. Klarmann D. (2000) Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood 96: 265a–265a.
38. Leissinger C.A. Berntorp E. Biasioli C. Carpenter S. Jo H. Kavakli K. (2010) Prophylactic dosing of anti-inhibitor coagulant complex (FEIBA) reduces bleeding frequency in hemophilia A patients with inhibitors: results of the Pro-FEIBA study. Blood 116: 720–720.
39. Lindley C.M. Sawyer W.T. Macik B.G. Lusher J. Harrison J.F. Baird-Cox K. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55: 638–648.
40. Ludlam C.A. Smith M.P. Morfini M. Gringeri A. Santagostino E. Savidge G.F. (2003) A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 120: 808–813.
41. Lusher J. Ingerslev J. Roberts H. Hedner U. (1998a) Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 9: 119–128.
42. Lusher J.M. (1998b) Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 63: 7–10.
43. Lusher J.M. Blatt P.M. Penner J.A. Aledort L.M. Levine P.H. White G.C. (1983) Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 62: 1135–1138.
44. Lusher J.M. Roberts H.R. Davignon G. Joist J.H. Smith H. Shapiro A. (1998b) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 4: 790–798.
45. Lusher J.M. Shapiro S.S. Palascak J.E. Rao A.V. Levine P.H. Blatt P.M. (1980) Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 303: 421–425.
46. Luu H. Ewenstein B. (2004) FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 10(Suppl. 2): 10–16.
47. Lyseng-Williamson K.A. Plosker G.L. (2007) Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 25: 1007–1029.
48. Manco-Johnson M.J. Abshire T.C. Shapiro A.D. Riske B. Hacker M.R. Kilcoyne R. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544.
49. Monroe D.M. Hoffman M. Oliver J.A. Roberts H.R. (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99: 542–547.
50. Monroe D.M. Hoffman M. Roberts H.R. (2002) Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22: 1381–1389.
51. Morfini M. Auerswald G. Kobelt R.A. Rivolta G.F. Rodriguez-Martorell J. Scaraggi F.A. (2007a) Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 13: 502–507.
52. Morfini M. Haya S. Tagariello G. Pollmann H. Quintana M. Siegmund B. (2007b) European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 13: 606–612.
53. Negrier C. Dargaud Y. Bordet J.C. (2006a) Basic aspects of bypassing agents. Haemophilia 12(Suppl. 6): 48–52.
54. Negrier C. Gomperts E.D. Oldenburg J. (2006b) The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 12: 4–13.
55. Negrier C. Goudemand J. Sultan Y. Bertrand M. Rothschild C. Lauroua P. (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 77: 1113–1119.
56. Nilsson I.M. Berntorp E. Lofqvist T. Pettersson H. (1992) Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232: 25–32.
57. Nilsson I.M. Hedner U. (1976) Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 16: 369–382.
58. Nilsson I.M. Hedner U. Bjorlin G. (1973) Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Ann Intern Med 78: 91–95.
59. Nilsson I.M. Jonsson S. Sundqvist S.B. Ahlberg A. Bergentz S.E. (1981) A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 58: 38–44.
60. Novo Nordisk (2010) NovoSeven® RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable, Lyophilized Powder, prescribing information. Novo Nordisk A/S: Bagsvaerd, Denmark.
61. O'Connell K.A. Wood J.J. Wise R.P. Lozier J.N. Braun M.M. (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295: 293–298.
62. Obergfell A. Auvinen M.K. Mathew P. (2008) Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 14: 233–241.
63. Ramgren O. (1962) A clinical and medico-social study of haemophilia in Sweden. Acta Med Scand Suppl 379: 111–190.
64. Rodriguez-Merchan E.C. Rocino A. Ewenstein B. Bartha L. Batorova A. Goudemand J. (2004) Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 10: 50–52.
65. Salaj P. Brabec P. Penka M. Pohlreichova V. Smejkal P. Cetkovsky P. (2009) Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 15: 752–759.
66. Santagostino E. Mancuso M.E. Rocino A. Mancuso G. Scaraggi F. Mannucci P.M. (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4: 367–371.
67. Shapiro A.D. Gilchrist G.S. Hoots W.K. Cooper H.A. Gastineau D.A. (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80: 773–778.
68. Sjamsoedin L.J. Heijnen L. Mauser-Bunschoten E.P. van Geijlswijk J.L. van Houwelingen H. van Asten P. (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 305: 717–721.
69. Soucie J.M. Cianfrini C. Janco R.L. Kulkarni R. Hambleton J. Evatt B. (2004) Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 103: 2467–2473.
70. Sumner W.T. Monroe D.M. Hoffman M. (1996) Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81: 533–543.
71. Thorland E.C. Drost J.B. Lusher J.M. Warrier I. Shapiro A. Koerper M.A. (1999) Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 5: 101–105.
72. Tjonnfjord G.E. (2004) Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 10(Suppl. 2): 41–45.
73. Tjonnfjord G.E. Brinch L. Gedde-Dahl T. Brosstad F.R. (2004) Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 10: 174–178.
74. Tjonnfjord G.E. Holme P.A. (2007) Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 3: 527–531.
75. Turecek P.L. Varadi K. Gritsch H. Schwarz H.P. (2004) FEIBA: mode of action. Haemophilia 10(Suppl. 2): 3–9.
76. Valentino L.A. (2010) Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 16: 263–271.
77. Varadi K. Negrier C. Berntorp E. Astermark J. Bordet J.C. Morfini M. (2003) Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 1: 2374–2380.
78. Villar A. Aronis S. Morfini M. Santagostino E. Auerswald G. Thomsen H.F. (2004) Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10: 352–359.
79. Young G. Ebbesen L.S. Viuff D. Di Paola J. Konkle B.A. Negrier C. (2008a) Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 19: 276–282.
80. Young G. Shafer F.E. Rojas P. Seremetis S. (2008b) Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 14: 287–294.